MarketCap
Facebook
X
Telegram
Marrone Bio Innovations Financial Ratios 2021-2010 | MBII
Brief overview of Marrone Bio Innovations's market valuation
Current figures are compared with the company's own five-year history for 2017–2021.
The valuation comparison uses P/S 2.92x (median 6.44x), P/B 4.36x (median 5.76x). Valuation is roughly 39.5% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
The latest available business-quality ratios are ROE -55.8%, ROA -19%, ROCE -51.9%. Current return ratios are negative, materially weakening the fundamental profile.
Current PEG is 0.27x; the market pays comparatively little per unit of expected growth.
The cash cycle accelerated by 376.1 days to 210.2 days. Less capital is tied up in operations.
Valuation takeaway
Marrone Bio Innovations's discount may reflect genuine profitability issues rather than market inefficiency alone.
Annual Financial Ratios Marrone Bio Innovations
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-7.8 | -12.3 | -3.6 | -7.7 | -1.0 | -6.9 | -0.5 | -1.5 | -4.4 | - | - | - |
P/S |
2.9 | 6.4 | 4.6 | 7.3 | 9.2 | 20.1 | 2.3 | 8.3 | 16.4 | - | - | - |
EPS |
-0.1 | -0.1 | -0.3 | -0.2 | -1.1 | -0.3 | -1.8 | -2.3 | -3.7 | -32.5 | -10.6 | - |
EV (Enterprise Value) |
167 M | 281 M | 179 M | 170 M | 117 M | 121 M | 75.7 M | 84.5 M | 145 M | 58.4 M | 41.7 M | -4.29 M |
EBITDA per Share |
-0.07 | -0.09 | -0.22 | -0.17 | -0.72 | -0.87 | -1.47 | -2.06 | -3.52 | -18.5 | -10.2 | - |
EV/EBITDA |
-14.1 | -20.6 | -7.0 | -9.7 | -5.6 | -5.6 | -2.1 | -1.8 | -4.7 | -2.5 | -3.3 | - |
PEG |
0.27 | 0.37 | 0.14 | 0.19 | 0.02 | 0.31 | -0.02 | -0.05 | 0.09 | - | - | - |
P/B |
4.4 | 7.9 | 5.8 | 12.0 | -0.6 | -1.8 | -11.0 | 2.3 | 3.6 | - | - | - |
P/CF |
-13.0 | -15.5 | -6.4 | -8.0 | -1.4 | -2.2 | -0.6 | -1.6 | -4.1 | - | - | - |
ROE % |
-55.83 | -64.21 | -157.80 | -156.25 | 61.06 | 25.87 | 2162.61 | -155.45 | -80.04 | 52.25 | 38.65 | - |
ROA % |
-19.02 | -24.84 | -51.12 | -43.41 | -83.78 | -16.98 | -61.41 | -66.93 | -44.68 | -114.85 | -134.24 | - |
ROCE % |
-51.95 | -29.40 | -54.20 | -55.33 | -154.22 | -76.98 | -67.00 | -105.55 | -58.32 | 462.42 | -198.55 | - |
Current Ratio |
1.5 | 1.6 | 1.5 | 1.4 | 0.4 | 0.6 | 1.0 | 1.8 | 2.3 | 0.5 | 0.2 | - |
DSO |
96.1 | 76.3 | 53.7 | 48.6 | 358.8 | 402.9 | 77.0 | 111.3 | 143.0 | 72.4 | - | - |
DIO |
163.1 | 173.8 | 225.3 | 302.0 | 317.4 | 336.3 | 428.0 | 490.4 | 443.2 | 205.2 | - | - |
DPO |
49.0 | 62.1 | 69.8 | 91.9 | 89.9 | 65.0 | 154.7 | 199.2 | 165.4 | 88.6 | - | - |
Operating Cycle |
259.2 | 250.1 | 279.1 | 350.6 | 676.2 | 739.2 | 505.0 | 601.7 | 586.2 | 277.6 | - | - |
Cash Conversion Cycle |
210.2 | 188.0 | 209.3 | 258.7 | 586.3 | 674.2 | 350.2 | 402.5 | 420.8 | 189.0 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Marrone Bio Innovations
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | -0.04 | - | -0.03 | -0.02 | -0.02 | - | -0.04 | -0.02 | -0.05 | - | -0.14 | -0.06 | -0.04 | -0.15 | -0.04 | -0.04 | -0.04 | -0.24 | -0.27 | -0.25 | -0.31 | -0.32 | -0.29 | -0.28 | -0.38 | -0.45 | -0.4 | -0.45 | -0.49 | -0.66 | -0.59 | -0.5 | -0.52 | -0.63 | -0.47 | -2.36 | -8.59 | -14.11 | -10.94 | -3.13 | -4.2 | - | - | - | - |
EBITDA per Share |
- | - | - | -0.03 | - | -0.01 | -0.01 | -0.01 | - | -0.02 | - | -0.03 | - | -0.07 | -0.05 | -0.03 | - | -0.02 | -0.03 | -67 | - | -0.16 | -0.15 | -0.22 | - | -0.15 | -0.15 | -0.28 | - | -0.25 | -0.35 | -0.43 | -0.64 | -0.48 | -0.4 | -0.46 | -0.58 | -0.63 | -4.38 | -4.08 | - | -4.2 | -2.77 | - | - | - | - | - |
ROE % |
-58.11 | -58.11 | -58.11 | -67.33 | -34.12 | -60.36 | -55.21 | -74.71 | -65.49 | -132.13 | -299.02 | -328.93 | -300.68 | -413.62 | -371.58 | -200.50 | -180.82 | -53.30 | -9.17 | 33.60 | 75.33 | 86.63 | 98.09 | 117.90 | 184.37 | 704.00 | 551.47 | 423.18 | 283.04 | -311.31 | -233.11 | -161.33 | -138.33 | -120.28 | -89.06 | -69.63 | -65.53 | -11.70 | 19.00 | 20.82 | 23.03 | 18.59 | 5.27 | - | - | - | - | - |
ROA % |
-19.53 | -19.53 | -19.53 | -23.30 | -13.34 | -21.75 | -19.39 | -24.69 | -20.92 | -41.82 | -47.66 | -51.48 | -42.63 | -74.01 | -61.90 | -56.42 | -55.02 | -43.64 | -57.67 | -64.33 | -75.98 | -72.97 | -64.49 | -60.71 | -57.47 | -55.98 | -53.87 | -63.12 | -67.41 | -72.95 | -79.38 | -68.75 | -66.12 | -62.28 | -51.72 | -53.24 | -52.90 | -86.32 | -119.08 | -118.87 | -50.61 | -40.86 | -11.58 | - | - | - | - | - |
ROCE % |
-51.89 | -51.89 | -51.89 | -60.45 | -29.75 | -53.31 | -46.61 | -62.57 | -54.01 | -93.80 | -254.13 | -284.34 | -261.59 | -284.60 | -265.25 | -121.18 | -83.29 | -68.17 | -29.96 | 6.37 | 46.19 | 68.90 | 83.02 | 137.70 | 121.82 | 14.86 | -90.74 | -170.19 | -240.06 | -286.86 | -220.56 | -152.24 | -129.92 | -111.64 | -88.19 | -66.82 | -51.73 | -15.47 | 6.79 | -12.81 | - | 7.74 | 5.06 | - | - | - | - | - |
Current Ratio |
- | - | - | 1.4 | 1.5 | 1.6 | 1.7 | 1.7 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.1 | 1.2 | 1.4 | 1.6 | 1.7 | 1.4 | 0.4 | 0.5 | 0.6 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 | 1.1 | 1.3 | 1.6 | 1.8 | 1.8 | 2.8 | 2.1 | 2.3 | 3.0 | 0.3 | 2.5 | 0.5 | 0.5 | 0.5 | - | - | - | - | - |
DSO |
- | - | - | 104.1 | - | 127.3 | 101.5 | 97.7 | - | 104.5 | 76.9 | 77.3 | - | 96.6 | 105.4 | 60.1 | - | 65.5 | 72.0 | 76.8 | 61.1 | 79.0 | 97.7 | 128.1 | 95.8 | 82.8 | 83.5 | 120.4 | 89.1 | 80.0 | 69.6 | 87.8 | 148.5 | 122.3 | 142.6 | 180.1 | 117.0 | 201.9 | 102.6 | 151.2 | 91.5 | 367.2 | 89.8 | - | - | - | - | - |
DIO |
- | - | - | 174.9 | - | 179.8 | 121.8 | 146.1 | - | 147.1 | 125.8 | 170.2 | - | 233.3 | 229.1 | 193.1 | - | 293.4 | 289.5 | 404.4 | - | 324.0 | 189.8 | 332.7 | - | 300.2 | 242.3 | 354.4 | - | 397.3 | 341.1 | 557.6 | 805.7 | 327.6 | 405.8 | 705.8 | 404.1 | 749.1 | 249.7 | 533.6 | - | 853.3 | 325.0 | - | - | - | - | - |
DPO |
- | - | - | 56.4 | - | 57.3 | 37.3 | 45.8 | - | 35.9 | 71.7 | 110.5 | - | 55.0 | 66.5 | 49.8 | - | 54.5 | 61.8 | 130.7 | - | 107.8 | 71.5 | 88.1 | - | 81.2 | 70.7 | 92.7 | - | 82.7 | 110.7 | 226.1 | 372.2 | 143.7 | 220.2 | 359.7 | 165.0 | 399.3 | 117.6 | 211.8 | - | 368.5 | 140.3 | - | - | - | - | - |
Operating Cycle |
- | - | - | 279.1 | - | 307.1 | 223.3 | 243.9 | - | 251.6 | 201.6 | 246.1 | - | 316.5 | 338.6 | 260.4 | - | 313.5 | 290.8 | 427.0 | 61.1 | 417.1 | 279.4 | 447.6 | 121.8 | 400.7 | 313.1 | 454.3 | 112.0 | 440.0 | 340.1 | 587.5 | 954.2 | 403.6 | 477.6 | 739.3 | 512.8 | 829.2 | 797.6 | 684.9 | 91.5 | 1220.5 | 414.8 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 222.7 | - | 249.7 | 186.0 | 198.1 | - | 215.7 | 129.9 | 135.5 | - | 225.3 | 241.9 | 198.4 | - | 258.4 | 239.9 | 315.2 | 61.1 | 278.0 | 192.0 | 343.8 | 121.8 | 350.0 | 272.6 | 386.1 | 112.0 | 361.7 | 278.9 | 408.2 | 582.0 | 251.4 | 281.0 | 477.2 | 347.8 | 554.8 | 540.9 | 473.1 | 91.5 | 852.0 | 274.4 | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Marrone Bio Innovations, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Agricultural inputs industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Акрон
AKRN
|
- | - | - |  Russia |
 |
The Mosaic Company
MOS
|
$ 22.3 | 0.09 % | $ 7.08 B |  USA |
 |
ФосАгро
PHOR
|
- | - | - | Russia |
 |
China Green Agriculture
CGA
|
- | 0.51 % | $ 27.6 M |  China |
 |
The Scotts Miracle-Gro Company
SMG
|
$ 69.31 | 2.64 % | $ 3.99 B | USA |
 |
CVR Partners, LP
UAN
|
$ 123.06 | -0.66 % | $ 1.3 B | USA |
 |
American Vanguard Corporation
AVD
|
$ 2.57 | 1.58 % | $ 73.1 M | USA |
 |
CF Industries Holdings
CF
|
$ 125.07 | -1.29 % | $ 20.3 B | USA |
 |
FMC Corporation
FMC
|
$ 11.3 | -3.38 % | $ 1.41 B | USA |
 |
Yield10 Bioscience
YTEN
|
- | 15.32 % | $ 46.6 M | USA |
 |
Bioceres Crop Solutions Corp.
BIOX
|
$ 0.34 | -1.44 % | $ 21.5 M |  Argentina |
 |
Corteva
CTVA
|
$ 89.25 | 0.53 % | $ 60.7 B | USA |
 |
Origin Agritech Limited
SEED
|
$ 1.01 | 1.0 % | $ 7.57 M | China |
 |
ICL Group Ltd
ICL
|
$ 5.28 | -0.38 % | $ 6.81 B |  Israel |
 |
Arcadia Biosciences
RKDA
|
$ 0.64 | 2.89 % | $ 876 K | USA |
 |
Intrepid Potash
IPI
|
$ 34.22 | -0.67 % | $ 445 M | USA |
 |
Nutrien Ltd.
NTR
|
$ 68.1 | -0.64 % | $ 33.1 B |  Canada |